Literature DB >> 31098867

Quality assessment using EQ-5D-5L after lung surgery for non-small cell lung cancer (NSCLC) patients.

Ryo Koide1,2, Ami Kikuchi1,2, Masahiro Miyajima3, Taijiro Mishina3, Yuki Takahashi3, Miho Okawa3, Izumi Sawada1, Junko Nakajima3, Atsushi Watanabe3, Toru Mizuguchi4,5.   

Abstract

OBJECTIVES: Aim of this study was to elucidate an alteration of quality of life (QOL) score before and after video-assisted thoracoscopic surgery (VATS) for non-small cell lung cancer (NSCLC) patients using the 5-level EuroQol-5D questionnaire (EQ-5D-5L). We also investigated how the preoperative QOL scores affected the postoperative clinical outcome prospectively.
METHODS: Between July 2018 and December 2018, 24 consecutive NSCLC patients who underwent VATS were recruited. The EQ-5D-5L for Japanese was used with face-to-face interviews to estimate the utility values of QOL.
RESULTS: QOL scores were significantly declined after surgery (0.81 ± 0.19 vs. 0.74 ± 0.11: P = 0.049). The levels of EQ-5D-5L questionnaire were not significantly different before and after surgery except Q4 (pain control). The levels of Q4 were significantly worsened after surgery (1.33 ± 0.56 vs. 1.88 ± 0.61, P < 0.001). Operation time and bleeding in the preoperative low-QOL score group (N = 13) was longer (215.4 ± 52.3 min. vs. 173.5 ± 42.3 min., respectively: P = 0.045) and more (116.2 ± 152.7 ml vs. 22.7 ± 20.1 ml, respectively: P = 0.049) than those in the high-QOL score group (N = 11).
CONCLUSIONS: QOL survey for lung cancer patients using EQ-5D-5L is simple and useful to identify the issue facing at the medical team. Preoperative low QOL score could be a predicting factor for the longer operation time and more bleeding.

Entities:  

Keywords:  EuroQol; Lung surgery; Pain; Quality of life; VATS

Mesh:

Year:  2019        PMID: 31098867     DOI: 10.1007/s11748-019-01136-0

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  15 in total

Review 1.  Health outcomes in economic evaluation: the QALY and utilities.

Authors:  Sarah J Whitehead; Shehzad Ali
Journal:  Br Med Bull       Date:  2010-10-29       Impact factor: 4.291

2.  Poor preoperative patient-reported quality of life is associated with complications following pulmonary lobectomy for lung cancer.

Authors:  Cecilia Pompili; Galina Velikova; John White; Matthew Callister; Jonathan Robson; Sandra Dixon; Kevin Franks; Alessandro Brunelli
Journal:  Eur J Cardiothorac Surg       Date:  2017-03-01       Impact factor: 4.191

Review 3.  Clinical and public health perspectives and applications of health-related quality of life measurement.

Authors:  S Ebrahim
Journal:  Soc Sci Med       Date:  1995-11       Impact factor: 4.634

4.  A measure of quality of life after abdominal surgery.

Authors:  David R Urbach; Julie L Harnish; Jodi Herold McIlroy; David L Streiner
Journal:  Qual Life Res       Date:  2006-08       Impact factor: 4.147

Review 5.  Incidence of mortality and morbidity related to postoperative lung injury in patients who have undergone abdominal or thoracic surgery: a systematic review and meta-analysis.

Authors:  Ary Serpa Neto; Sabrine N T Hemmes; Carmen S V Barbas; Martin Beiderlinden; Ana Fernandez-Bustamante; Emmanuel Futier; Markus W Hollmann; Samir Jaber; Alf Kozian; Marc Licker; Wen-Qian Lin; Pierre Moine; Federica Scavonetto; Thomas Schilling; Gabriele Selmo; Paolo Severgnini; Juraj Sprung; Tanja Treschan; Carmen Unzueta; Toby N Weingarten; Esther K Wolthuis; Hermann Wrigge; Marcelo Gama de Abreu; Paolo Pelosi; Marcus J Schultz
Journal:  Lancet Respir Med       Date:  2014-11-13       Impact factor: 30.700

Review 6.  A review of 250 ten-year survivors after pneumonectomy for non-small-cell lung cancer.

Authors:  Marc Riquet; Pierre Mordant; Ciprian Pricopi; Antoine Legras; Christophe Foucault; Antoine Dujon; Alex Arame; Françoise Le Pimpec-Barthes
Journal:  Eur J Cardiothorac Surg       Date:  2013-10-16       Impact factor: 4.191

Review 7.  Toward the realization of a better aged society: messages from gerontology and geriatrics.

Authors:  Hidenori Arai; Yasuyoshi Ouchi; Masayuki Yokode; Hideki Ito; Hiroshi Uematsu; Fumio Eto; Shinichi Oshima; Kikuko Ota; Yasushi Saito; Hidetada Sasaki; Kazuo Tsubota; Hidenao Fukuyama; Yoshihito Honda; Akihisa Iguchi; Kenji Toba; Takayuki Hosoi; Toru Kita
Journal:  Geriatr Gerontol Int       Date:  2012-01       Impact factor: 2.730

Review 8.  Quality of life of patients with lung cancer.

Authors:  Jacek Polanski; Beata Jankowska-Polanska; Joanna Rosinczuk; Mariusz Chabowski; Anna Szymanska-Chabowska
Journal:  Onco Targets Ther       Date:  2016-02-29       Impact factor: 4.147

9.  Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D.

Authors:  Takeru Shiroiwa; Takashi Fukuda; Shunya Ikeda; Ataru Igarashi; Shinichi Noto; Shinya Saito; Kojiro Shimozuma
Journal:  Qual Life Res       Date:  2015-08-25       Impact factor: 4.147

Review 10.  Understanding the Use of Composite Endpoints in Clinical Trials.

Authors:  C Eric McCoy
Journal:  West J Emerg Med       Date:  2018-06-04
View more
  3 in total

Review 1.  Choosing the right survey: the lung cancer surgery.

Authors:  Cecilia Pompili; Michael Koller; Galina Velikova
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

2.  Comparative effectiveness of smartphone healthcare applications for improving quality of life in lung cancer patients: study protocol.

Authors:  Geun Dong Lee; Sei Won Lee; Jang Ho Lee; Jae Hwa Jeong; Wonjun Ji; Hui Jeong Lee; Yura Lee; Min-Woo Jo; Seockhoon Chung; Sung-Cheol Yun; Chang-Min Choi; Jong Won Lee
Journal:  BMC Pulm Med       Date:  2022-05-02       Impact factor: 3.320

3.  Current standard values of health utility scores for evaluating cost-effectiveness in liver disease: A meta-analysis.

Authors:  Tomohiro Ishinuki; Shigenori Ota; Kohei Harada; Masaki Kawamoto; Makoto Meguro; Goro Kutomi; Hiroomi Tatsumi; Keisuke Harada; Koji Miyanishi; Toru Kato; Toshio Ohyanagi; Thomas T Hui; Toru Mizuguchi
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.